Innovative Research

Groundwork develops new tools, data, and research to reframe economic policy debates and tell different stories about how the economy works and who it works for.

Groundwork Collaborative

One Year of the Republican Tax Law: New Yorkers Are Still Paying For It

One year after the passage of the so-called One Big Beautiful Bill Act, New Yorkers are grappling with the consequences.

July 8, 2026
Groundwork Collaborative

Trump’s Two-Way Tariff Rip-Off: Consumers Pay More, Corporations Get Paid Back

Trump's tariff policies have created a new corporate cash grab.

July 2, 2026
Groundwork Collaborative

Gridlocked: How Public Power Can Build the Grid of the Future and Lower Bills Now

After decades of deregulation and complacency, the time is ripe to embark on a grand national project to fundamentally rethink how energy is generated and distributed in the U.S.

July 1, 2026
Collaboration

Backyard Barbecue Blues: Many Fourth of July Staples Up 20% this Year

Many go-to summertime staples — including ground beef, popsicles, and potato salad — are up more than 20% in just one year, nearly five times the overall inflation rate.

June 30, 2026
Groundwork Collaborative

Paid for by You: One Year of the Republican Tax Law

One year after the passage of the so-called One Big Beautiful Bill Act (OBBBA), families across the country are still grappling with a cost of living crisis exacerbated by President Trump’s economic agenda.

June 29, 2026
Collaboration

Cutting Out the Middleman: A Public Option for Pharmacy Benefits

Americans pay more for prescription drugs than patients in any other wealthy country, and it's not just due to exorbitant pricing by drug manufacturers. Three corporate middlemen — CVS Caremark, Express Scripts, and OptumRx — control key channels in the drug supply chain, including roughly 80% of prescription claims in the U.S. Their business model artificially inflates and benefits from high drug prices. Government regulation and enforcement is not enough.

June 23, 2026
Collaboration

AmericaRx: Manufacturing Affordable Drugs in the Public Interest

The U.S. pharmaceutical industry is a highly profitable, highly extractive industry. While it delivers scientific breakthroughs and develops life-saving treatments for illnesses that were once incurable, the industry fails Americans on numerous fronts. We lack a business model that can discipline or provide an alternative to the price gouging rampant in both branded and generic drug markets. In this brief, we propose a solution: AmericaRx.

June 23, 2026
Collaboration

The Price of Corruption: How Trump’s Pay-to-Play Administration is Driving Up Costs for Working Families

From health care to travel to energy, Trump’s corrupt wheelings and dealings have drained money from American families.

June 3, 2026
Groundwork Collaborative

Big Oil Racks Up Windfall Profits While Consumers Pay Higher Prices

As Trump’s war in Iran sends gas prices soaring, major oil companies are cashing in.

May 26, 2026
Collaboration

As Summer Kicks Off, Memorial Day Staples Up 13% on Average and Travel Prices Soar

As Americans kick off the summer this Memorial Day weekend, Trump’s mishandling of the economy will leave families paying much more to enjoy the warmer season.

May 21, 2026
Load More